{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:27:32Z","timestamp":1760059652165,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP17H05088","JP23ym0126810","JP24ym0126810"],"award-info":[{"award-number":["JP17H05088","JP23ym0126810","JP24ym0126810"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP17H05088","JP23ym0126810","JP24ym0126810"],"award-info":[{"award-number":["JP17H05088","JP23ym0126810","JP24ym0126810"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Society for Inherited Metabolic Diseases","award":["JP17H05088","JP23ym0126810","JP24ym0126810"],"award-info":[{"award-number":["JP17H05088","JP23ym0126810","JP24ym0126810"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lysosomal storage diseases are caused by defective lysosomal function, such as impaired lysosomal enzyme activities, which include more than 70 different diseases. Although biomarkers and therapies have been developed to date for some of them, many others remain challenging to diagnose and treat. In this study, an elevated level of Globotriaosylsphingosine (Lyso-Gb3), an already known biomarker for Fabry disease, was confirmed in the knock-out cells of the GLA, GNPTAB, and PSAP genes and models for Fabry, mucolipidosis II\/III (ML II\/III), and combined saposin deficiency, respectively. Lyso-Gb3 was high in ML II\/III patient skin fibroblasts compared with normal cells and was decreased after total lysosomal enzyme supplementation. There have been no useful biomarkers reported in ML II\/III until now. This study shows that Lyso-Gb3 is elevated in ML II\/III patient cells and is decreased by treatment, indicating that Lyso-Gb3 is a potential biomarker for ML II\/III.<\/jats:p>","DOI":"10.3390\/ijms26136275","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:56:54Z","timestamp":1751353014000},"page":"6275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular Lyso-Gb3 Is a Biomarker for Mucolipidosis II"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-1628","authenticated-orcid":false,"given":"Seigo","family":"Terawaki","sequence":"first","affiliation":[{"name":"Department of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Lipidome Lab Co., Ltd., Akita 010-0825, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toko","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan"},{"name":"Department of Pediatrics, University of Osaka, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6709","authenticated-orcid":false,"given":"Norio","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Osaka, Suita 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-7299","authenticated-orcid":false,"given":"Takanobu","family":"Otomo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35283","DOI":"10.1074\/jbc.M111.267930","article-title":"Lysosomal storage causes cellular dysfunction in mucolipidosis II skin fibroblasts","volume":"286","author":"Otomo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moriwaki, T., Terawaki, S., and Otomo, T. (2024). Impaired lysosomal acidity maintenance in acid lipase-deficient cells leads to defective autophagy. J. Biol. Chem., 300.","DOI":"10.1016\/j.jbc.2024.105743"},{"key":"ref_4","first-page":"173","article-title":"Mutation in VPS33A affects metabolism of glycosaminoglycans: A new type of mucopolysaccharidosis with severe systemic symptoms","volume":"27","author":"Kondo","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cyske, Z., Gaffke, L., Pierzynowska, K., and W\u0119grzyn, G. (2024). Mucopolysaccharidosis-Plus Syndrome: Is This a Type of Mucopolysaccharidosis or a Separate Kind of Metabolic Disease?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179570"},{"key":"ref_6","unstructured":"Desnick, R.J., Ioannou, Y.A., and Eng, C.M. (2025, June 20). The Online Metabolic and Molecular Bases of Inherited Disease, Part 16: Lysosomal Disorders, \u03b1-Galactosidase A Deficiency: Fabry Disease. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225546984."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2018","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109110","DOI":"10.1016\/j.ymgme.2025.109110","article-title":"The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review","volume":"145","author":"Ramaswami","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy","volume":"26","author":"Sanz","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)40540-1","article-title":"Saposins: Structure, function, distribution, and molecular genetics","volume":"33","author":"Kishimoto","year":"1992","journal-title":"J. Lipid Res."},{"key":"ref_12","unstructured":"Sandhoff, K., Kolter, T., Harzer, K., Schepers, U., and Remmel, N. (2025, June 20). The Online Metabolic and Molecular Bases of Inherited Disease, Part 16: Lysosomal Disorders, Sphingolipid Activator Proteins. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225543732."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/hmg\/10.9.927","article-title":"A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation","volume":"10","author":"Befekadu","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12017-010-8133-7","article-title":"Pathology and current treatment of neurodegenerative sphingolipidoses","volume":"12","author":"Eckhardt","year":"2011","journal-title":"Neuromolecular Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nm1305","article-title":"Mucolipidosis II is caused by mutations in GNPTA encoding the alpha\/beta GlcNAc-1-phosphotransferase","volume":"11","author":"Tiede","year":"2005","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Khan, S.A., and Tomatsu, S.C. (2020). Mucolipidoses Overview: Past, Present, and Future. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186812"},{"key":"ref_17","unstructured":"Braulke, T., Raas-Rothschild, A., and Kornfeld, S. (2025, June 20). The Online Metabolic and Molecular Bases of Inherited Disease, Part 16: Lysosomal Disorders, I-Cell Disease and Pseudo-Hurler Polydystrophy: Disorders of Lysosomal Enzyme Phosphorylation and Localization. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225544648."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1096\/fasebj.1.6.3315809","article-title":"Trafficking of lysosomal enzymes","volume":"1","author":"Kornfeld","year":"1987","journal-title":"FASEB J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Spiewak, J., Doykov, I., Papandreou, A., H\u00e4llqvist, J., Mills, P., Clayton, P.T., Gissen, P., Mills, K., and Heywood, W.E. (2023). New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210177"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1083\/jcb.201407077","article-title":"Mannose 6 phosphorylation of lysosomal enzymes controls B cell functions","volume":"208","author":"Otomo","year":"2015","journal-title":"J. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1534\/g3.113.005777","article-title":"The genomic and transcriptomic landscape of a HeLa cell line","volume":"3","author":"Landry","year":"2014","journal-title":"G3"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lipidomics Standards Initiative Consortium (2019). Lipidomics needs more standardization. Nat. Metab., 1, 745\u2013747.","DOI":"10.1038\/s42255-019-0094-z"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:08Z","timestamp":1760032868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":23,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136275"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136275","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}